Genmab A/S (NASDAQ:GMAB) Price Target Raised to $40.00

Genmab A/S (NASDAQ:GMAB) had its price target raised by HC Wainwright from $39.00 to $40.00 in a research note released on Wednesday morning,Benzinga reports. The firm currently has a buy rating on the stock. HC Wainwright also issued estimates for Genmab A/S’s Q1 2026 earnings at $0.15 EPS, Q2 2026 earnings at $0.53 EPS, Q3 2026 earnings at $0.53 EPS, Q4 2026 earnings at $0.54 EPS and FY2026 earnings at $1.75 EPS.

A number of other research firms also recently weighed in on GMAB. Jefferies Financial Group initiated coverage on shares of Genmab A/S in a research report on Tuesday. They set a “buy” rating and a $41.50 target price for the company. Zacks Research downgraded shares of Genmab A/S from a “strong-buy” rating to a “hold” rating in a research note on Friday, October 31st. Truist Financial restated a “buy” rating and issued a $48.00 target price (down previously from $49.00) on shares of Genmab A/S in a report on Thursday, November 6th. Wall Street Zen lowered Genmab A/S from a “buy” rating to a “hold” rating in a research report on Saturday, February 7th. Finally, Johnson Rice reissued a “buy” rating on shares of Genmab A/S in a research note on Monday, October 27th. Six equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Genmab A/S has an average rating of “Moderate Buy” and a consensus target price of $41.30.

Genmab A/S Price Performance

Shares of GMAB opened at $29.29 on Wednesday. The company has a quick ratio of 6.01, a current ratio of 2.02 and a debt-to-equity ratio of 0.86. The stock has a market cap of $18.82 billion, a PE ratio of 18.90, a PEG ratio of 16.53 and a beta of 0.90. Genmab A/S has a 12-month low of $17.24 and a 12-month high of $35.43. The business has a 50-day simple moving average of $32.15 and a two-hundred day simple moving average of $29.92.

Genmab A/S (NASDAQ:GMAB) last posted its earnings results on Tuesday, February 17th. The company reported $0.05 earnings per share for the quarter, missing analysts’ consensus estimates of $0.46 by ($0.41). The business had revenue of $1.06 billion for the quarter, compared to the consensus estimate of $1.06 billion. Genmab A/S had a return on equity of 17.35% and a net margin of 25.89%. Analysts anticipate that Genmab A/S will post 1.45 earnings per share for the current fiscal year.

Institutional Trading of Genmab A/S

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Founders Capital Management boosted its holdings in Genmab A/S by 40.0% in the fourth quarter. Founders Capital Management now owns 1,400 shares of the company’s stock worth $43,000 after acquiring an additional 400 shares in the last quarter. Parallel Advisors LLC raised its position in shares of Genmab A/S by 11.3% during the third quarter. Parallel Advisors LLC now owns 4,139 shares of the company’s stock worth $127,000 after purchasing an additional 419 shares during the period. CWM LLC lifted its holdings in shares of Genmab A/S by 18.8% in the 4th quarter. CWM LLC now owns 2,739 shares of the company’s stock worth $84,000 after purchasing an additional 433 shares in the last quarter. Jones Financial Companies Lllp grew its position in Genmab A/S by 29.1% in the 3rd quarter. Jones Financial Companies Lllp now owns 1,951 shares of the company’s stock valued at $57,000 after purchasing an additional 440 shares during the period. Finally, Osaic Holdings Inc. grew its position in Genmab A/S by 37.8% in the 2nd quarter. Osaic Holdings Inc. now owns 1,603 shares of the company’s stock valued at $33,000 after purchasing an additional 440 shares during the period. 7.07% of the stock is owned by institutional investors.

More Genmab A/S News

Here are the key news stories impacting Genmab A/S this week:

• Positive Sentiment: HC Wainwright raised its FY2026 EPS view and bumped the price target to $40, increasing quarterly estimates for Q2–Q4 even as it trimmed Q1. The firm maintains a “Buy” rating, which likely helped lift the stock. HC Wainwright Increases Genmab A/S (NASDAQ:GMAB) Price Target to $40.00
• Positive Sentiment: Reported full-year revenue strength: Genmab posted ~19% revenue growth to about $3.7B in 2025, driven by proprietary medicine sales — a revenue beat/trajectory that supports higher earnings forecasts and investor confidence. Genmab (GMAB) reports 19% revenue growth to $3.7B in 2025 driven by proprietary medicine sales
• Neutral Sentiment: Jefferies initiated coverage on GMAB (coverage starts attention and can add liquidity); the initiation itself is noteworthy but the direction impact depends on the published rating/details. Jefferies Financial Group Initiates Coverage on Genmab A/S (NASDAQ:GMAB)
• Neutral Sentiment: Disclosure of transactions by managerial employees and closely associated persons was filed (routine regulatory reporting). Without details on buys vs. sells, this is primarily informational. Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
• Neutral Sentiment: Analyst roundup and commentary (Benzinga piece) summarizes multiple analyst views — useful context but no single catalyst. 3GMAB : A Glimpse Into The Expert Outlook On Genmab Through 4 Analysts
• Neutral Sentiment: Short interest data in the feed appears anomalous (shows zero shares/ratio) and is not a reliable signal for current positioning.
• Negative Sentiment: Recent quarterly results included a sizeable EPS miss (reported $0.05 vs. consensus ~$0.46) despite revenue roughly in line — that miss is a primary reason the stock had pressure earlier and still weighs on near-term sentiment.

Genmab A/S Company Profile

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.